NEW YORK (GenomeWeb News) — The National Heart Lung and Blood Institute will use TrimGen's eQ-PCR Warfarin Genotyping Kit in a clinical trial designed to find out if a gene-based strategy will benefit patients who are at high risk for warfarin sensitivity.
Sensitivity to the blood-thinning drug can result in a higher risk of thromboembolism and bleeding, and can lead doctors to discontinue the therapy early.
The multi-center study, Clarification of Optimal Anticoagulation through Genetics (COAG), will compare two warfarin dosing approaches, including one group that will receive genotype-guided dosing and another group that will receive dosing using clinical data.
Trimgen said it will contribute the tests used for the study, which will begin in April 2009 and is expected to last until 2012.